الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 212 |  |  |
| | | from | 212 | | |
Abstract
• In the present study, 103 patients received adjuvant TAM for treatment of breast carcinoma were analyzed for CYP2D6*4 genotypesThe minimal allele frequency of CYP2D6*4 in the Egyptian sample studied was 23%. This frequency is matching with Caucasians and some previous Egyptian studies but different from other populations like Saudi Arabia people and some other Egyptian studies.• Intra-population difference (i.e. between Egyptians) in allele frequency may relate to the tests used to detect this allele, sample size, gender, healthy or diseased subjects and inbreeding Cytochrome P450 2D6*4 genotyping analysis may predict increased endometrial thickness as an adverse effect of TAM, but not other drug adverse effects. CYP2D6*4 genotyping is not predictor of cancer relapse during TAM therapy.